The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis

被引:180
作者
Middeldorp, S
Henkens, CMA
Koopman, MMW
van Pampus, ECM
Hamulyák, K
van der Meer, J
Prins, MH
Büller, HR
机构
[1] Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, NL-1105 AZ Amsterdam, Netherlands
[2] Ziekenhuis Rivienland, Dept Intern Med, NL-4002 WP Tiel, Netherlands
[3] Univ Hosp Maastricht, Dept Haematol, NL-6229 HX Maastricht, Netherlands
[4] Univ Groningen Hosp, Dept Haematol, Div Haematostasis Thrombosis & Rheol, NL-9713 EZ Groningen, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
关键词
thrombophlebitis; thromboembolism; heterozygote; mutation; factor;
D O I
10.7326/0003-4819-128-1-199801010-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The factor V Leiden mutation is a genetic defect associated with an increased incidence of Venous thromboembolism. When the incidence of venous thromboembolism in relatives of patients known to have the mutation outweighs the disadvantages of prophylactic strategies, family screening may be necessary. Objective: To determine the incidence of venous thromboembolism in first-degree relatives of symptomatic carriers of the factor V Leiden mutation. Design: Retrospective blinded study. Setting: University hospitals. Participants: 437 first-degree relatives of 112 heterozygous propositi and 30 relatives of 6 homozygous propositi. Measurements: Before DNA testing, information on previous venous thromboembolism and concomitant risk factors was obtained. Relatives with and without the FV: Q(506) mutation were compared. Results: The annual incidence of thromboembolism in relatives of heterozygous propositi was 0.45% (95% CI, 0.28% to 0.61%) in those with the mutation and 0.10% (CI, 0.02% to 0.19%) in those without the mutation (relative risk, 4.2 [CI, 1.8 to 9.9]). Among carriers, the incidence increased from 0.25% (CI, 0.12% to 0.49%) in the 15- to 30-year-old age group to 1.1% (CI, 0.24% to 3.33%) in persons older than 60 years of age. Half of the episodes of Venous thromboembolism occurred spontaneously, 20% were related to surgery, and 30% were associated with pregnancy or use of oral contraceptives. Conclusions: The observed low annual risk for venous thromboembolism in persons carrying the factor V Leiden mutation does not seem to outweigh the risks for bleeding associated with coumarin prophylaxis or justify discouragement of the use of oral contraceptives. A general policy of screening the families of all patients with the factor V Leiden mutation does not seem to be indicated. The observations in this moderate-size, retrospective study need to be confirmed by prospective follow-up studies.
引用
收藏
页码:15 / +
页数:7
相关论文
共 21 条
[1]  
ALLAART CF, 1995, BRIT MED J, V311, P910
[2]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[3]  
BRIDEY F, 1995, THROMB HAEMOSTASIS, V74, P1382
[4]   Are we ready for factor V Leiden screening? [J].
Dahlback, B .
LANCET, 1996, 347 (9012) :1346-1347
[5]   Resistance to activated protein C in an unselected population of patients with pulmonary embolism [J].
Desmarais, S ;
deMoerloose, P ;
Reber, G ;
Minazio, P ;
Perrier, A ;
Bounameaux, H .
LANCET, 1996, 347 (9012) :1374-1375
[6]  
Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257
[7]   Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis [J].
Friederich, PW ;
Sanson, BJ ;
Simioni, P ;
Zanardi, S ;
Huisman, MV ;
Kindt, I ;
Prandoni, P ;
Buller, HR ;
Girolami, A ;
Prins, MH .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (12) :955-+
[8]   ACTIVATED PROTEIN-C RESISTANCE CAUSED BY ARG506GLN MUTATION IN FACTOR VA [J].
GREENGARD, JS ;
SUN, X ;
XU, X ;
FERNANDEZ, JA ;
GRIFFIN, JH ;
EVATT, B .
LANCET, 1994, 343 (8909) :1361-1362
[9]   DEFICIENCIES OF COAGULATION-INHIBITING AND FIBRINOLYTIC PROTEINS IN OUTPATIENTS WITH DEEP-VEIN THROMBOSIS [J].
HEIJBOER, H ;
BRANDJES, DPM ;
BULLER, HR ;
STURK, A ;
TENCATE, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (22) :1512-1516